Return to Main PagePre-Register

CATHERINE DEJEAN

Dejean

Catherine Dejean, Ph.D. is medical physicist at Centre Antoine-LACASSAGNE, Nice, France.

As general secretary, she is an active member of SFPM (French society of medical physics) but also of ESTRO (European Society for Radiotherapy and Oncology) and AAPM (American Association of Physicist in Medicine). She is involved in quality control in clinical trials for scientific societies and UNITRAD (Research Group in Oncological Radiotherapy). 

Involved in new technologies implementation from project management, radioprotection towards clinical routine, she also participates in teaching at physics training course, medical study and for post-graduate programs. MSc trainees have been supervised especially on skin dose and 50kV. 

Main research and clinical interests: quality control in clinical trials, pediatric irradiation, new technological development in radiotherapy.  

Since 2019, she’s AERO president, involved in this peer-to-peer community based on collaboration and peer-review to develop clinical innovation dissemination. 

MISCHA HOOGEMAN

Hoogeman

Mischa Hoogeman, Ph.D. is head of medical physics at Erasmus MC Cancer Institute, Head of Medical Physics & Informatics of the Holland Proton Therapy Center as well as professor at the Erasmus University Rotterdam on High-Precision and Adaptive Radiotherapy and at the Delft University of Technology.

The overarching aim of his research is to widen the therapeutic window by the development, implementation and evaluation of high-precision radiotherapy techniques. He leads the research group that developed and implemented a novel plan-of-the-day technique to accurately irradiate the highly- deformable target volume of cervical cancer patients. 

Current research aims to further improve this technique, translate it to Stereotactic Body Radiotherapy, and to clinically evaluate the benefit in terms of reduction in side effects and improved quality of life.

With the introduction of proton therapy in the Netherlands, the focus of research has shifted to proton therapy. Research in this area includes developing online-adaptive proton therapy by near-real-time daily re-optimization of the treatment plan, quantifying the uncertainties during the delivery of proton therapy that may impair the theoretical benefit, and developing methods to account for those by designing robust treatment plans.

RAPHAEL MOECKLI

Moeckli

Raphaël Moeckli completed his MSc degree at the Ecole Polytechnique Fédérale de Lausanne (EPFL). He is certified Swiss medical physicists since 1999, head of the radiation therapy group in Institute of Radiation Physics and head physicist in the Radio-Oncology Department at the Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland. 

As « Maître d’Enseignement et de Recherche » and Privat Docent, both in Lausanne University. His main fields of research are TomoTherapy®, multicriteria optimisation and FLASH therapy.

He is and has been director and expert for various national and international PhD thesis juries. He has published more than 60 papers in peer-reviewed journal. 

As past president of the Swiss Society of Radiobiology and Medical Physics he has been active in different working groups having issued Swiss recommendations about good practice in radiation therapy.

He has been member of different scientific committees of ESTRO as well as other Swiss and international meetings.

HALE CAGLAR

Prof. Dr. Hale Başak Çağlar was born in Ankara on March 29th, 1975.

She completed her primary and secondary education at TED Ankara College in between 1981-1992. She completed her education at the Faculty of Medicine at the  Gazi University, Turkey, between 1992-1998, and finalized her specialization education at the Radiation Oncology Department, Marmara University, Turkey with her thesis, titled “Acute skin and pulmonary radiation toxicities in breast cancer patients treated with radiotherapy in the adjuvant setting”.

She worked at the Brachytherapy Unit, Radiation Oncology Department, Faculty of Medicine, Hacettepe University, Turkey, in the Radiation Oncology Department, Faculty of Medicine, Marmara University, Turkey between 2003-2009; she has been active at Harvard Joint Committee, Dana Farber Cancer Institute and at the Maternity Hospital, Harvard University, United States, between 2006-2007.  

She served as an Assistant Professor at the Radiation Oncology Department of the Faculty of Medicine, Marmara University, between 2008-2010, and in the Faculty of Medicine, Acıbadem University, Turkey from 2010 to 2013.

While she served as the Chairwoman and Program Director at the Radiation Oncology Department, Faculty of Medicine, Medipol University in between 2013-2015, she further served thereat as the Chairwoman, Program Director, and Professor until 2017. Having started working at the Anadolu Medical Center, Turkey in 2017, Prof. Dr. Çağlar has been going on serving as a radiation oncology specialist and radiation oncology director since then.

UMBERTO RICARDI

Ricardi

Dr. Ricardi is Chairman of Radiation Oncology at the University of Turin and Director of the Department of Oncology at the Health and Science Academic Hospital in Turin, Italy. Full Professor of Radiation Oncology at University of Turin, Italy and dean of School of Medicine at the University of Turin.

He worked as Dean of the Graduation School for Radiographers and Radiation Therapy Therapists (2012-2016). Dr. Ricardi is Director of Post-Graduation Residency School in Radiation Oncology at University of Turin.

Dr. Ricardi’s main areas of clinical research interests during these years are lymphoma and leukemia, lung cancer, CNS tumor and pediatric oncology.

Expert in the development of cutting-edge technologies in Radiation Oncology, Dr. Ricardi has authored more than 270 full research papers. He participated as invited speaker in several national and international conferences.

He is active in many educational activities, both at national and international level. From this point of view, he is very active within the ESTRO School (Faculty for the following Courses: CNS Tumors, Combined Modality Treatments, Hematological Malignancies, Pediatric Radiation Oncology: serving for the latter also as course director).

Dr. Ricardi, is member of many national and international scientific societies such as ESTRO, ASTRO, Honorary Member of SEOR (Spanish Society of Radiation Oncology), Honorary Member of DEGRO (German Society Radiation Oncology), member of IASLC (International Association Study Lung Cancer), being also member of IASLC ART (Advanced Radiotherapy) Committee and Steering Committee Member of ILROG (International Lymphoma Radiation Oncology Group).

Currently, Dr. Ricardi is President of the ESTRO (European Society for Radiotherapy and Oncology).

VINCENT KHOO

Khoo

Vincent Khoo is a Clinical Oncologist at The Royal Marsden Hospital, London, UK as well Honorary Oncologist at St George’s Hospital and Honorary Reader at Institute of Cancer Research, University of London; Adjunct Professor, Department of Medical Imaging and Radiation Sciences, Monash University, and Honorary Associate Professor, Department of Medicine, Melbourne University, and Austin Health, Australia.

He specializes in urological cancers, with interests in technical radiotherapy from stereotactic to image-guided intensity-modulated RT; adaptive RT; brachytherapy; multimodality imaging; systemic therapy and clinical trials (phase I – IV studies); as well as evaluation of genetic, and bio-prognostic markers.

He is a member of several national and international research study groups, scientific committees, advisory and editorial boards including UK NCRI Clinical Study Group, Genetic Prostate Groups, ESTRO, ESMO and ECCO scientific committees. 

Vincent Khoo has published over 240 papers. 

FLORENCE HUGUET

Huguet

Florence Huguet is head of the department of Radiation Oncology in Tenon Hospital, Assistance Publique, Hôpitaux de Paris, France. She is professor of Radiation Oncology at the Paris Sorbonne University.

Florence Huguet is specialized in cancers of the gastrointestinal tract as well as head and neck. Her aim is to introduce the most cutting-edge technology in radiation oncology to the treatment of GI and H&N malignancies, including intensity-modulated radiation therapy, image-guided radiation therapy, and stereotactic body radiotherapy, with the intent of reducing toxicity and improving our results from radiation therapy.

In addition to her interest in technical advances in radiation oncology, she is also involved in the development of therapeutic protocols combining radiation, chemotherapy, targeted agents, and immunotherapy for gastrointestinal and head and neck cancers. Interested in quality of life and late effects after radiation therapy, she has become an expert in radiation therapy quality assurance.